Scholar Rock (NASDAQ:SRRK) Stock Price Up 5.9% - Should You Buy?

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report)'s share price rose 5.9% on Thursday . The stock traded as high as $32.59 and last traded at $32.64. Approximately 388,290 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 1,266,727 shares. The stock had previously closed at $30.82.

Analysts Set New Price Targets

SRRK has been the topic of a number of recent analyst reports. Wedbush restated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Lifesci Capital upgraded shares of Scholar Rock to a "strong-buy" rating in a research report on Tuesday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Scholar Rock currently has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Trading Down 0.1%

The company has a market cap of $3.25 billion, a PE ratio of -14.57 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The company has a 50 day simple moving average of $30.37 and a two-hundred day simple moving average of $36.15.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the business posted ($0.59) EPS. Sell-side analysts forecast that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other news, insider Akshay Vaishnaw sold 6,750 shares of the company's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $200,610.00. Following the transaction, the insider now directly owns 616,205 shares of the company's stock, valued at approximately $18,313,612.60. This represents a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey S. Flier sold 6,075 shares of Scholar Rock stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.73, for a total value of $180,609.75. Following the sale, the director now directly owns 24,070 shares of the company's stock, valued at approximately $715,601.10. The trade was a 20.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 181,798 shares of company stock worth $6,284,738 in the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors have recently made changes to their positions in SRRK. Global Retirement Partners LLC raised its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares in the last quarter. CWM LLC increased its stake in shares of Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after purchasing an additional 602 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Scholar Rock during the 4th quarter valued at $85,000. Federated Hermes Inc. acquired a new stake in shares of Scholar Rock in the 1st quarter valued at $71,000. Finally, Strs Ohio bought a new stake in Scholar Rock in the first quarter worth $77,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.